The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types ...
A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...
Effect of fusion of radiomic, pathomic, and clinical biomarkers on multi-scale tumor biology and OS stratification in HNSCC receiving standard of care (SOC). Phase 2 trial of ozuriftamab vedotin ...
Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed the study, ...
GH Research PLC has provided updates on its GH001 treatment for depression, reporting completion of the Open-Label Extension analysis that shows a 73% remission rate at six months without serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback